The ETH Zurich software security spinout had raised at least $5.2m before it was purchased by Snyk yesterday for an undisclosed sum.

Trustbridge Partners has acquired a majority stake in WeWork China, a SoftBank-backed company that was at one point valued at $5bn.

TriNetX had raised $102m in funding from investors including Merck & Co, Mitsui and Itochu before agreeing to a purchase by Carlyle.

Two weeks after filing to go public, Grail has instead accepted an $8bn acquisition offer from Illumina, which had spun off the cancer diagnostics technology developer five years ago.

Zhonggu Logistics has filed for a $218m on the Shanghai Stock Exchange, providing exits to Zhonggu Shipping and SoftBank.

The Washington State University neurological drug developer has gone public after issuing 12 million shares priced at $17 each.

Novartis-backed Inflazome, which advances University of Queensland and Trinity College Dublin research to develop treatments for inflammation, has been bought by Roche for $448m.

Inflazome, which advances University of Queensland and Trinity College Dublin research to develop treatments for inflammation, has been bought by Roche for $448m.